Insider Selling: Repare Therapeutics Inc. (NASDAQ:RPTX) Director Sells 14,328 Shares of Stock

Last updated on Monday, June 21, 2021 | 2021 MarketBeat

Repare Therapeutics Inc. (NASDAQ:RPTX) Director Todd Foley sold 14,328 shares of the business's stock in a transaction dated Thursday, June 17th. The stock was sold at an average price of $33.80, for a total value of $484,286.40. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Todd Foley also recently made the following trade(s):

  • On Wednesday, June 9th, Todd Foley sold 15,523 shares of Repare Therapeutics stock. The stock was sold at an average price of $34.68, for a total value of $538,337.64.
  • On Monday, June 7th, Todd Foley sold 10,186 shares of Repare Therapeutics stock. The shares were sold at an average price of $32.68, for a total value of $332,878.48.
  • On Thursday, June 3rd, Todd Foley sold 9,824 shares of Repare Therapeutics stock. The shares were sold at an average price of $31.92, for a total value of $313,582.08.
  • On Wednesday, May 26th, Todd Foley sold 10,590 shares of Repare Therapeutics stock. The shares were sold at an average price of $32.76, for a total value of $346,928.40.
  • On Monday, May 24th, Todd Foley sold 9,782 shares of Repare Therapeutics stock. The shares were sold at an average price of $34.12, for a total value of $333,761.84.
  • On Thursday, May 20th, Todd Foley sold 4,387 shares of Repare Therapeutics stock. The shares were sold at an average price of $34.69, for a total value of $152,185.03.
  • On Tuesday, May 18th, Todd Foley sold 10,312 shares of Repare Therapeutics stock. The shares were sold at an average price of $34.16, for a total value of $352,257.92.

Shares of RPTX traded up $0.55 during trading hours on Monday, hitting $34.57. 9,087 shares of the stock were exchanged, compared to its average volume of 148,639. Repare Therapeutics Inc. has a 12-month low of $21.45 and a 12-month high of $46.44. The firm has a market capitalization of $1.28 billion and a P/E ratio of -8.92. The stock has a 50-day moving average price of $32.90.

Repare Therapeutics (NASDAQ:RPTX) last issued its quarterly earnings results on Thursday, May 13th. The company reported ($0.58) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.51) by ($0.07). The company had revenue of $0.17 million during the quarter. Equities research analysts anticipate that Repare Therapeutics Inc. will post -2.44 earnings per share for the current year.

Several research analysts have recently weighed in on the company. Berenberg Bank assumed coverage on Repare Therapeutics in a research note on Monday, March 1st. They set a "buy" rating and a $51.00 target price for the company. Morgan Stanley upped their target price on Repare Therapeutics from $41.00 to $45.00 and gave the stock an "overweight" rating in a research note on Monday, April 19th. Finally, Zacks Investment Research downgraded Repare Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of "Buy" and an average price target of $40.20.

Several institutional investors and hedge funds have recently modified their holdings of RPTX. Swiss National Bank purchased a new stake in shares of Repare Therapeutics during the fourth quarter worth approximately $713,000. BlackRock Inc. purchased a new stake in Repare Therapeutics in the 4th quarter valued at $12,485,000. Banque Cantonale Vaudoise grew its holdings in Repare Therapeutics by 50.0% in the 4th quarter. Banque Cantonale Vaudoise now owns 3,000 shares of the company's stock valued at $103,000 after buying an additional 1,000 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in Repare Therapeutics in the 4th quarter valued at $213,000. Finally, Wells Fargo & Company MN purchased a new stake in Repare Therapeutics in the 4th quarter valued at $87,000. Hedge funds and other institutional investors own 70.24% of the company's stock.

About Repare Therapeutics

Repare Therapeutics Inc, a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair.

Read More: What is the Federal Reserve?

Insider Buying and Selling by Quarter for Repare Therapeutics (NASDAQ:RPTX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: What causes a recession?


7 Things You Need To Know About Cryptocurrency

The Cryptocurrency Market Is About To Boil Over

The cryptocurrency was quiet for years, but it’s starting to boil over once again. With the price of Bitcoin up 550%, it certainly seems like the sky is the limit.

Whether or not you choose to trade Bitcoin or any other cryptocurrency, it is important to understand what it is and the trends driving it.

The bottom line, however, is that the world’s money is flowing onto the blockchain, and the use of cryptocurrency is growing at an exponential rate.

View the "7 Things You Need To Know About Cryptocurrency".


MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.